Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integral DiagnosticsASX:IDX -0.97%69 EV-to-EBIT is 26.77 as of Jul. 26, 2026, which is 43% above its 10-year median of 18.67. GuruFocus rates ASX:IDX with a GF Score™ of 69/100 and a GF Value™ of A$2.79 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Integral Diagnostics ranks worse than 61.54% on this metric.
The historical rank and industry rank for Integral Diagnostics's EV-to-EBIT or its related term are showing as below:
ASX:IDX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -26.25 Med: 18.67 Max: 45.96
Current: 26.77
During the past 10 years, the highest EV-to-EBIT of Integral Diagnostics was 45.96. The lowest was -26.25. And the median was 18.67.
ASX:IDX's EV-to-EBIT is ranked worse than 61.54% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.46
vs ASX:IDX: 26.77
Integral Diagnostics (ASX:IDX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Integral Diagnostics's Enterprise Value for the quarter that ended in Dec. 2025 was A$1,516.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Integral Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$49.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics EV-to-EBIT Related Terms
Integral Diagnostics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integral Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's EV-to-EBIT falls into.
Integral Diagnostics's current Enterprise Value is A$1,335.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Integral Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$49.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a EV-to-EBIT of 26.77 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Integral Diagnostics and its competitors. This is 43% above median its historical median of 18.67. According to the industry distribution chart, Integral Diagnostics ranks #64 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 61.5%.
Is Integral Diagnostics' EV-to-EBIT too high?
Integral Diagnostics' current EV-to-EBIT of 26.77 is 43% above median its 10-year median of 18.67. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.46. Integral Diagnostics' value of 26.77 is 19.2% above this industry median. Based on the distribution chart, Integral Diagnostics ranks #64 out of 104 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #64 out of 104 companies for EV-to-EBIT. This places Integral Diagnostics in the lower half of its industry. The industry median EV-to-EBIT is 22.46. Integral Diagnostics' value of 26.77 is 19.2% above this benchmark. While the company's 10-year median is 18.67 vs. the industry median of 22.46, Integral Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.46, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current EV-to-EBIT of 26.77 is 19.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current EV-to-EBIT is 26.77, which is 43% above median its own 10-year median of 18.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.79, compared to a current price of A$2.05 — trading 26.5% below its estimated fair value. The current EV-to-EBIT is 26.77, which is 43% above median its 10-year median of 18.67 and 19.2% above the Medical Diagnostics & Research industry median of 22.46. Integral Diagnostics' overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current EV-to-EBIT is 26.77 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.05 is trading 26.5% below its estimated GF Value™ of A$2.79.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
EV-to-EBIT: 26.77 (43% above median its 10-year median of 18.67)
GF Value™: A$2.79 vs. price of A$2.05 (26.5% below fair value)
Industry Position: 19.2% above the Medical Diagnostics & Research median (#64 of 104)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
69GF Score
Get the complete analysis for ASX:IDX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
